Osteoporosis

Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase in fracture risk.

Also Called / Synonyms

• Osteoporosis (ICD-10: M80-M82)
• Fragility bone disease
• Metabolic bone disease (osteoporosis type)
• Osteopenia (the precursor state, defined below)
• Senile osteoporosis (age-related form)
• Postmenopausal osteoporosis (estrogen-deficiency-driven form)
• Secondary osteoporosis (due to drugs or underlying disease)

Definition by Bone Mineral Density (BMD)

The World Health Organization (WHO) established the operational definition of osteoporosis based on BMD measurement by dual-energy X-ray absorptiometry (DXA). The T-score compares a patient's BMD to the peak bone mass of a healthy young adult reference population (20-29 years of age, same sex and ethnicity).

The -2.5 threshold was chosen because it identifies approximately 30% of postmenopausal women at the hip, a prevalence that correlates with the lifetime fracture risk in this population. The diagnosis can be made in the presence of a fragility fracture even if T-score is not ≤ -2.5, though this is less common.

Classification by Etiology

Primary Osteoporosis

Primary osteoporosis occurs without an identifiable secondary cause and is subdivided by age and temporal association:

• Postmenopausal osteoporosis (Type I): Occurs in women within 15-20 years of menopause due to accelerated estrogen-deficiency-induced bone loss. Characterized by trabecular bone loss, leading to vertebral and distal forearm fractures.
• Senile osteoporosis (Type II): Occurs in both sexes after age 70-75 due to age-related decline in bone formation, decreased calcium absorption, and secondary hyperparathyroidism . Affects both cortical and trabecular bone, leading to hip and vertebral fractures.
• Idiopathic osteoporosis in young adults: Rare, occurs in premenopausal women and men <50 years with no secondary cause; BMD is typically very low, and management is less standardized.

Secondary Osteoporosis

Secondary osteoporosis results from an identifiable disease, medication, or lifestyle factor. Common causes include:

• Glucocorticoid therapy (most common drug-induced cause; >5 mg/day prednisone equivalent for ≥3 months ^[8]D5).
• Aromatase inhibitors, proton pump inhibitors, antiretroviral drugs, antiepileptic drugs, antipsychotics, and antidepressants, each through distinct mechanisms that may involve gut microbiota dysbiosis ^[8]D5.
• Endocrine disorders: Hypogonadism, hyperthyroidism, hyperparathyroidism, Cushing syndrome.
• Gastrointestinal disorders: Malabsorption (celiac disease, inflammatory bowel disease), post- gastrectomy .
• Rheumatologic/inflammatory diseases: Rheumatoid arthritis, systemic lupus erythematosus.
• Chronic kidney disease (renal osteodystrophy), liver disease, organ transplantation.
• Immobilization (e.g., cerebral palsy, spinal cord injury; low to moderate certainty evidence shows higher prevalence in adults with CP versus those without ^[1]A1a).

Classification by Anatomic Site

While osteoporosis is systemic, fractures occur at characteristic sites: vertebral bodies (thoracolumbar), proximal femur (hip), distal forearm (Colles fracture), and pelvis (osteoporotic pelvic fractures, OFP, common in elderly women ^[6]B2b). The skeletal distribution of bone loss varies by type.

Clinical Significance

Osteoporosis is the most common metabolic bone disease worldwide, affecting an estimated 200 million women. It causes over 8.9 million fractures annually, one every 3 seconds. Following a hip fracture , mortality is 20-24% in the first year, and many survivors lose independent mobility. The disease is underdiagnosed, especially in men ^[3]A1a and in special populations such as adults with cerebral palsy ^[1]A1a.

Pearl: The WHO T-score definition (≤ -2.5 at the hip or spine) establishes the diagnostic threshold for osteoporosis, but fracture risk is determined by multiple factors beyond BMD; secondary osteoporosis should always be excluded, particularly in men, premenopausal women, and patients with fragility fractures at non-typical sites ^[3]A1a[8]D5.

The burden of osteoporosis is not uniform across populations. Among adults with cerebral palsy, osteoporosis prevalence ranges from 4.4% to 21.7% and fracture prevalence from 8% to 39%, with higher rates in females and those with low mobility ^[1]A1a. In the general population, osteoporosis is most common in postmenopausal women and older adults; a Chinese cohort of postmenopausal women with osteoporosis had a mean age of 66.6 years and a mean lumbar spine T-score of -2.8 ^[15]B2b. Patients with cancer, especially high-mortality types, undergo BMD testing more frequently and have a higher relative risk of osteoporotic fracture than matched non-cancer patients ^[9]B2b.

Demographic Distribution

Age and sex are the strongest non-modifiable risk factors. Osteoporosis prevalence rises steeply after age 50, and women are affected more often than men across all populations studied ^{[1]A1a[15]B2b}. Among adults with cerebral palsy, female sex is associated with higher osteoporosis and osteopenia prevalence ^[1]A1a. Ethnicity data are limited in the provided references, but the studies include Asian (Chinese, Malaysian) and predominantly White (Danish, German) cohorts, suggesting a global burden ^{[13]B2b[15]B2b[16]B3b}.

Risk Factors

Risk factors for osteoporosis and fracture can be grouped into non-modifiable and modifiable categories. The table below summarizes key factors with available effect estimates.

Special Populations

• Cerebral palsy: Adults with CP have a disproportionately high burden of osteoporosis and fractures, driven by immobility, anticonvulsant use, and low BMI ^[1]A1a.
• Cancer survivors: Breast cancer survivors on aromatase inhibitors and those with chemotherapy-induced ovarian failure are at elevated risk ^[12]A1a. High-mortality cancers (e.g., lung, pancreatic) show the highest relative fracture rates ^[9]B2b.
• Normocalcemic hyperparathyroidism: This underdiagnosed condition accounts for over 1 in 10 osteoporosis referrals and independently predicts structural bone compromise ^[14]B2b.
• Migraine: Women with frequent migraine have impaired bone status, possibly mediated by vitamin D deficiency and elevated PTH ^[17]B3b.

Controversies and Guideline Disagreement

No major controversies exist in the epidemiology of osteoporosis from the provided references. However, the optimal screening strategy for secondary causes (e.g., universal PTH measurement vs. selective testing) remains debated; the high prevalence of NCHPTH (12.5%) in one referral cohort supports a low threshold for testing ^[14]B2b.

Pearl: Osteoporosis prevalence varies widely by population, from 4.4% in adults with cerebral palsy to over 12% of referrals for metabolic bone disease having normocalcemic hyperparathyroidism as an underlying cause; screening for secondary risk factors such as glucocorticoid use, aromatase inhibitors, and NCHPTH is essential to identify modifiable contributors ^{[1]A1a[14]B2b}.

Bone remodeling is a continuous, coupled process of resorption by osteoclasts followed by formation by osteoblasts, and in osteoporosis this balance is pathologically shifted in favor of resorption. The fundamental mechanism is an increase in osteoclast activity and a relative or absolute decrease in osteoblast function, leading to net bone loss and microarchitectural deterioration. This imbalance arises through a complex interplay of molecular signaling pathways, hormonal changes, and cellular senescence.

The RANK/RANKL/OPG Axis: The Final Common Pathway

The receptor activator of nuclear factor-κB (RANK) ligand (RANKL), expressed on the surface of osteoblasts and marrow stromal cells, binds to RANK on osteoclast precursors to drive their differentiation, activation, and survival. Osteoprotegerin (OPG), a soluble decoy receptor also produced by osteoblasts, neutralizes RANKL and inhibits osteoclastogenesis. In osteoporosis, the OPG-to-RANKL ratio is decreased, unleashing osteoclast-mediated bone resorption. Estrogen deficiency, the dominant driver of postmenopausal osteoporosis , directly upregulates RANKL expression and downregulates OPG production in T cells and bone marrow stromal cells, shifting the balance toward resorption. Glucocorticoid excess, a common cause of secondary osteoporosis, similarly suppresses OPG while promoting RANKL synthesis by osteoblasts.

Wnt/β-Catenin Signaling and Osteoblast Failure

The canonical Wnt/β-catenin pathway is the principal anabolic signal for osteoblasts. Binding of Wnt proteins to the LRP5/LRP6 and Frizzled receptor complex stabilizes β-catenin, which translocates to the nucleus and promotes transcription of osteoblast differentiation genes (RUNX2, OSX). In osteoporosis, Wnt signaling is antagonized by secreted inhibitors such as sclerostin (produced by osteocytes) and Dickkopf-1 (DKK-1). Mechanical unloading and estrogen deficiency both increase sclerostin expression, suppressing bone formation. The clinical importance of this pathway is confirmed by the therapeutic success of romosozumab, a monoclonal antibody that neutralizes sclerostin and simultaneously stimulates formation while modestly reducing resorption. Mutations in LRP5 cause osteoporosis-pseudoglioma syndrome, and common polymorphisms in LRP5 are associated with bone mineral density variation in the general population.

Estrogen Deficiency: The Dominant Threat in Women

Estrogen maintains bone mass by restraining osteoclast activity and preserving osteoblast and osteocyte viability. It acts through estrogen receptor-α (ERα) on both osteoclasts and osteoblasts: on osteoclasts, it reduces RANKL-induced differentiation and promotes apoptosis; on osteoblasts, it enhances proliferation and type I collagen synthesis. After menopause , estrogen levels fall by 80-90%, removing this restraint. The result is a rapid phase of bone loss, up to 2-5% of trabecular bone per year in the first 5-10 years, followed by a slower, age-related phase driven by secondary hyperparathyroidism and declining osteoblast function. In postmenopausal women, the early loss preferentially affects trabecular bone (vertebrae, distal radius), whereas cortical bone (femoral neck) erodes more slowly but progressively from the endosteal surface ^[18]A1a.

Parathyroid Hormone: Catabolic and Anabolic Dualism

Parathyroid hormone (PTH) exerts opposing effects depending on its pattern of exposure. Continuous elevation, as seen in secondary hyperparathyroidism from vitamin D deficiency or renal insufficiency, is catabolic: it stimulates RANKL expression on osteoblasts and thus drives osteoclast-mediated resorption. Intermittent, once-daily administration of teriparatide (PTH 1-34) is anabolic: it preferentially activates Wnt signaling and promotes osteoblast recruitment and survival. In osteoporosis, age-related declines in renal function and vitamin D status often produce mild secondary hyperparathyroidism, which contributes to cortical bone loss. PTH also enhances peri-implant osseointegration in osteoporotic bone by stimulating osteoblast activity and increasing bone-implant contact ^[19]A1a.

The Osteocyte Network and Mechanotransduction

Osteocytes, the most abundant bone cells, are embedded within the mineralized matrix and form a lacunocanalicular network that senses mechanical load and microdamage. They orchestrate remodeling by secreting RANKL (stimulating resorption at targeted sites) and sclerostin (inhibiting formation globally). In osteoporosis, osteocyte apoptosis is increased, which triggers localized osteoclast recruitment and releases pro-resorptive signals. The polycystin protein complex (PC1 and PC2) on the osteocyte cilium acts as a mechanosensor: deformation of the cilium by fluid flow shear stress activates intracellular calcium signaling and suppresses sclerostin production. Loss of polycystin function impairs this mechanotransduction, reducing the bone's adaptive response to loading and contributing to age-related bone loss ^[24]D5.

Cellular Senescence and Mitochondrial Dysfunction

Aging accumulates senescent cells in the bone microenvironment, including senescent osteocytes and preosteoblasts. These cells secrete a senescence-associated secretory phenotype (SASP), pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and matrix metalloproteinases, that promotes osteoclastogenesis and suppresses osteoblast differentiation. Mitochondrial dysfunction compounds this: impaired mitochondrial dynamics (fission/fusion balance) and increased oxidative stress in osteoblasts and osteoclasts disrupt energy metabolism and promote apoptosis ^[22]D5. Intercellular transfer of damaged mitochondria from osteocytes to adjacent cells may further propagate cellular dysfunction and bone loss ^[23]D5.

Microarchitectural Deterioration

The imbalance in remodeling does not merely reduce bone quantity; it degrades bone quality. Trabeculae become thinner, perforated, and eventually disconnected, reducing the bone's ability to withstand compressive loads. Cortical bone becomes more porous from increased Haversian remodeling and thins from endocortical resorption. These microarchitectural changes reduce bone strength disproportionately to the loss of bone mineral density, a 30% reduction in trabecular connectivity can halve vertebral strength. The clinical consequence is that fragility fractures occur at bone mineral density values that are still above the traditional osteoporotic threshold in some patients, especially in the elderly.

Pearl: The pathophysiology of osteoporosis converges on a final common pathway of RANKL-driven osteoclast activation and suppressed Wnt-mediated osteoblast activity, with estrogen deficiency at menopause representing the single most powerful driver in women. Understanding this axis explains the rationale for both antiresorptive (denosumab, bisphosphonates) and anabolic (teriparatide, romosozumab) therapies.

Osteoporosis is a silent disease until fracture occurs. The first clinical manifestation is often a low-trauma (fragility) fracture, one that results from a fall from standing height or less, or even from routine activities such as bending, lifting, or coughing. The classic fracture sites are the hip (proximal femur), vertebral body (spine), and distal forearm (wrist), though fractures of the humerus, pelvis, ribs, and tibia are also recognized as osteoporotic ^[26]A1c. A prior fragility fracture is the single strongest predictor of a subsequent fracture, doubling the risk of future events independent of bone mineral density (BMD) ^[27]A1a.

Presenting Symptoms

Vertebral fractures may present acutely with sudden-onset back pain at a characteristic level, often following minimal strain such as lifting a light object. The pain is mechanical, worsened by weight-bearing and relieved by lying flat, and typically radiates in a band-like distribution. However, two-thirds of vertebral fractures are clinically silent, discovered incidentally on chest or abdominal radiographs ^[26]A1c. Over time, cumulative vertebral compression leads to height loss, kyphosis (dowager's hump), and the characteristic physical finding of a rib-to-pelvis distance ≤ 2 fingerbreadths on lateral inspection. Progressive kyphosis can cause restrictive lung disease and early satiety due to abdominal compression.

Hip fractures present with acute onset of severe groin or lateral hip pain after a fall, an inability to bear weight, and external rotation with shortening of the affected limb. These fractures require urgent surgical fixation and are associated with 20-30% one-year mortality and profound functional decline ^[26]A1c.

Wrist fractures (typically Colles' fracture of the distal radius) present with dinner-fork deformity after a fall onto an outstretched hand. Although less morbid than hip fractures, they represent a sentinel event, particularly in women aged ≥50, and should trigger formal osteoporosis assessment ^[29]B3b. Indeed, hand fragility fractures are frequently excluded from routine screening pathways, representing a missed opportunity for secondary prevention; up to 80% of patients with hand fragility fractures are not offered DXA or treatment ^[29]B3b.

The FRAX Tool for Fracture Risk Assessment

The Fracture Risk Assessment Tool (FRAX) was developed to estimate the 10-year probability of hip fracture and major osteoporotic fracture (clinical spine, hip, forearm, or humerus) in untreated patients aged 40-90 years ^[27]A1a. FRAX integrates 12 clinical risk factors with or without femoral neck BMD (in g/cm²):

FRAX was derived and validated in 53 population-based cohorts comprising 307,205 men and women with a mean follow-up of 8.7 years ^[27]A1a. Each standard deviation decrease in femoral neck BMD approximately doubled hip fracture risk (age-adjusted hazard ratio ~2.0), with a similar but weaker gradient for other osteoporotic fractures ^[27]A1a.

Intervention thresholds vary by country. Most guidelines recommend pharmacotherapy when the 10-year major osteoporotic fracture probability exceeds 20% or the hip fracture probability exceeds 3% ^[26]A1c. Importantly, FRAX does not incorporate dose or duration of glucocorticoid exposure, fall risk, or the number of prior fractures, all of which may independently elevate risk. The tool therefore provides a starting point, not a complete assessment, and should be combined with clinical judgment.

Limitations and Emerging Tools

FRAX was developed from predominantly Caucasian cohorts and may underestimate fracture risk in Asian, Black, and Hispanic populations. Country-specific adaptations (e.g., FRAX-Taiwan, FRAX-Japan) partially address this, but calibration data remain sparse for many regions. FRAX also does not account for the bone-quality effects of diabetes, patients with type 2 diabetes have higher BMD yet paradoxically higher fracture risk, particularly when microvascular complications (retinopathy, nephropathy, neuropathy) are present ^[28]B2b.

Machine learning (ML) models integrating imaging features (radiomics from CT or MRI) and clinical variables are outperforming FRAX in pilot studies, with area under the receiver operating characteristic curves (AUC) of 0.82-0.91 for major fracture prediction compared to 0.68-0.74 for FRAX alone ^{[31]B2a[32]B2b}. These models remain investigational but may soon augment or replace traditional tools in fracture liaison services ^[32]B2b.

Pearl: A fragility fracture at any site, including the hand, should trigger formal osteoporosis evaluation with DXA and FRAX; up to 80% of such patients are currently missed, representing the largest single gap in secondary fracture prevention ^[29]B3b.

The diagnosis of osteoporosis rests on quantitative assessment of bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA), interpreted using the T-score classification established by the World Health Organization. A T-score of -2.5 or lower at the lumbar spine, total hip, or femoral neck defines osteoporosis; a T-score between -1.0 and -2.5 indicates osteopenia, and -1.0 or above is normal. This threshold was derived from the relationship between BMD and fracture risk in postmenopausal women and has been validated across populations ^[39]B2b. DXA remains the gold standard because of its low radiation dose, short scan time, and strong predictive value for fragility fractures.

Dual-Energy X-ray Absorptiometry (DXA), Gold Standard

Central DXA (spine and hip) is preferred over peripheral devices (heel, forearm) because central sites better predict hip fracture , the most devastating osteoporotic outcome. The lumbar spine is measured in the posterior-anterior projection, avoiding artifacts from degenerative changes or aortic calcification that can falsely elevate BMD. The femoral neck and total hip are the standard sites for diagnosis and monitoring; the forearm (33% radius) is used when spine or hip cannot be measured or in hyperparathyroidism. Precision assessment is essential: the least significant change (LSC) for a given DXA facility should be calculated to determine whether a BMD change is real. A follow-up DXA is typically performed 1 to 2 years after initiating therapy, though longer intervals may be appropriate for patients with stable BMD ^[9]B2b.

Screening and Case-Finding Strategies

Screening recommendations target populations at highest risk. The Osteoporosis Self-Assessment Tool (OST) uses age and weight to identify postmenopausal women and older men who should undergo DXA. A recent multi-cohort study in Asia demonstrated that the traditional fixed OST threshold performs poorly, especially in younger postmenopausal women, and supports age-dependent thresholds to improve sensitivity and specificity ^[39]B2b. In patients with cancer, BMD testing rates are higher than in matched non-cancer controls, but fracture risk varies by cancer type; high-mortality cancers show the highest relative rates of both testing and fracture, underscoring the need for targeted screening in oncology populations ^[9]B2b. The FRAX tool (not detailed here) integrates clinical risk factors with or without BMD to estimate 10-year fracture probability and can guide the decision to initiate pharmacotherapy.

Alternative Imaging Modalities

When DXA is unavailable or contraindicated, other techniques provide complementary information. Quantitative computed tomography (QCT) measures volumetric BMD (vBMD) and can distinguish cortical from trabecular bone, but involves higher radiation and cost. High-resolution peripheral QCT (HR-pQCT) assesses bone microarchitecture at the distal radius and tibia; a prospective study of romosozumab showed that while vBMD at the distal radius did not increase over 12 months, HR-pQCT detected modest improvements in bone strength, suggesting that standard DXA may underestimate treatment effects at certain sites ^[42]B2b. Artificial intelligence (AI) algorithms can derive BMD from routine radiographs (e.g., chest or lumbar X-rays) with strong agreement to DXA and comparable ability to predict incident fractures over 10 years, offering an opportunistic screening tool for populations with limited DXA access ^[41]B2b. Peripheral DXA and quantitative ultrasound (QUS) of the heel are used for initial risk stratification but are not diagnostic; a low result should prompt central DXA confirmation.

Diagnostic Algorithm

Step 1: Identify candidates for BMD testing using age-based screening (women ≥65, men ≥70) or risk factors (prior fragility fracture, glucocorticoid use, parental hip fracture, low body weight, smoking, excessive alcohol, secondary causes). Step 2: Perform central DXA of lumbar spine and hip. Step 3: Interpret T-score: ≤-2.5 = osteoporosis; -1.0 to -2.5 = osteopenia; ≥-1.0 = normal. Step 4: For osteopenia, calculate FRAX 10-year fracture probability; if hip fracture probability ≥3% or major osteoporotic fracture probability ≥20%, consider pharmacotherapy. Step 5: In patients with a fragility fracture and T-score >-2.5, diagnose osteoporosis based on clinical fracture history (this is a clinical diagnosis, not solely densitometric). Step 6: Evaluate for secondary causes if BMD is unexpectedly low or declines rapidly (see Differential Diagnosis section).

Pearl: DXA T-score ≤-2.5 at the spine or hip remains the diagnostic gold standard, but age-dependent screening thresholds (e.g., OST) and opportunistic AI-derived BMD from routine radiographs can improve case-finding in populations with limited DXA access ^{[39]B2b[41]B2b}.

A thorough evaluation for secondary causes is mandatory in all patients with osteoporosis, as up to 30% of men and 50% of premenopausal women have an identifiable underlying condition ^[3]A1a. Identifying a secondary cause alters management , treating the underlying disorder can improve bone density and reduce fracture risk independent of anti-osteoporosis pharmacotherapy. The workup begins with a detailed history (medications, comorbidities, family history), physical examination, and targeted laboratory testing, followed by imaging when indicated.

Glucocorticoid-Induced Osteoporosis

Glucocorticoid use is the most common drug-induced cause of secondary osteoporosis. Chronic oral glucocorticoid therapy (≥5 mg prednisone daily for ≥3 months) causes rapid bone loss and increased fracture risk, but even intermittent high-dose intravenous pulse methylprednisolone therapy reduces bone mineral density (BMD) at the lumbar spine and femoral neck ^[5]A1a. The effect is dose- and duration-dependent, with trabecular bone (spine) affected more than cortical bone. All patients on glucocorticoids for ≥3 months should receive calcium and vitamin D supplementation and be considered for bone-protective therapy (bisphosphonates or denosumab) ^[5]A1a.

Primary Hyperparathyroidism (PHPT)

PHPT is a common secondary cause, especially in postmenopausal women. BMD measurement at the lumbar spine, femoral neck, total hip, and distal 1/3 radius is recommended; osteoporosis at any site justifies parathyroidectomy ^[48]B3b. Forearm DXA is often neglected but is critical: up to 20% of PHPT patients have osteoporosis isolated to the distal radius, and a low forearm BMD is independently associated with higher serum calcium levels ^{[47]B3b[48]B3b}. Post-parathyroidectomy, BMD improves significantly at the lumbar spine and hip, but the radius may show less recovery ^[48]B3b.

Drug-Induced Osteoporosis (Other Agents)

Multiple drug classes contribute to secondary osteoporosis through direct effects on bone remodeling or via gut microbiota alterations ^[8]D5. Common offenders include:

• Aromatase inhibitors (e.g., anastrozole, letrozole) - used in breast cancer, cause accelerated bone loss.
• Proton pump inhibitors (PPIs) - long-term use reduces calcium absorption and increases fracture risk.
• Antiepileptic drugs (e.g., phenytoin , carbamazepine) - induce vitamin D deficiency and direct bone effects.
• Antiretroviral therapy - particularly tenofovir disoproxil fumarate, associated with renal phosphate wasting and bone loss.
• Antipsychotics and antidepressants - via hyperprolactinemia (hypogonadism) or direct effects ^[8]D5. A thorough medication history is essential; when possible, substitute with bone-friendly alternatives.

Hypogonadism and Other Endocrine Disorders

In men, hypogonadism is a leading secondary cause, often presenting with low testosterone and low BMD ^[3]A1a. Other endocrine disorders include hyperthyroidism, hypercortisolism (Cushing syndrome), and growth hormone deficiency. In children and young adults, chronic illnesses (e.g., inflammatory bowel disease, cystic fibrosis, juvenile idiopathic arthritis) and their treatments (glucocorticoids, methotrexate ) cause secondary osteoporosis ^[45]A1a.

Diagnostic Workup

Initial laboratory evaluation should include:

• Serum calcium, phosphate, alkaline phosphatase, creatinine, and 25-hydroxyvitamin D
• Intact PTH (if calcium elevated or borderline)
• Thyroid-stimulating hormone (TSH)
• Testosterone (in men) and estradiol (in premenopausal women if indicated)
• 24-hour urinary calcium (to exclude hypercalciuria and assess calcium absorption)
• Celiac serology (tissue transglutaminase antibodies) if malabsorption suspected
• Serum protein electrophoresis (if vertebral fractures or anemia suggest multiple myeloma )

If PHPT is suspected, forearm DXA is essential ^{[47]B3b[48]B3b}. Bone turnover markers (e.g., P1NP, CTX) may help assess bone loss rate but are not required for diagnosis.

Table: Common Secondary Causes of Osteoporosis

Pearl: A systematic evaluation for secondary causes, including glucocorticoid use, primary hyperparathyroidism, and hypogonadism, identifies a treatable underlying condition in up to 50% of premenopausal women and 30% of men with osteoporosis, and forearm DXA is essential for detecting PHPT-related bone loss ^{[3]A1a[47]B3b[48]B3b}.

Non-pharmacologic interventions form the foundation of osteoporosis management , complementing pharmacotherapy to reduce fracture risk. These strategies target modifiable risk factors, nutritional adequacy, physical activity, and fall prevention, and should be initiated at diagnosis and sustained lifelong.

Calcium and Vitamin D

Adequate calcium and vitamin D intake is essential for bone health, but supplementation provides fracture reduction only in individuals with low dietary intake. The 2026 systematic review and meta-analysis by Massé et al. (50 RCTs, N=58,000) found that calcium plus vitamin D supplementation reduced the risk of any fracture by 15% (RR 0.85, 95% CI 0.73-0.98) and hip fracture by 30% (RR 0.70, 95% CI 0.56-0.89) in institutionalized or vitamin D-deficient populations, but showed no benefit in community-dwelling adults with adequate baseline intake ^[50]A1a (1a). Total daily calcium intake (diet plus supplement) should be 1000-1200 mg; exceeding 1200 mg provides no additional benefit and may increase the risk of nephrolithiasis and cardiovascular events ^[50]A1a. Vitamin D supplementation of 800-1000 IU/day is recommended for adults aged ≥50 years, particularly those with limited sun exposure or malabsorption ^[50]A1a.

Warning: Avoid calcium supplementation exceeding 1200 mg/day total intake due to potential cardiovascular and renal risks ^[50]A1a.

Exercise

Weight-bearing and resistance exercise improve bone mineral density (BMD), muscle strength, and balance, thereby reducing fall and fracture risk. A 2026 network meta-analysis of 27 RCTs (N=2,183) demonstrated that moderate-to-vigorous aerobic exercise (≥150 min/week) significantly increased lumbar spine BMD (mean difference +0.023 g/cm², 95% CI 0.012-0.034) compared with no exercise ^[36]A1a (1a). The addition of resistance training (2-3 sessions/week) further improved hip BMD and trabecular bone score ^[36]A1a. In elderly patients with type 2 diabetes without osteoporosis, a 2-year structured exercise program (aerobic + resistance) increased trabecular bone score by 0.016 (95% CI 0.008-0.024) and preserved BMD at the femoral neck, while the control group lost bone ^[49]A1b (1b). Walking alone, even at low intensity, reduces osteoporosis risk: a UK Biobank prospective cohort (N=432,493) found that walking ≥30 min/day was associated with a 20% lower hazard of incident osteoporosis (HR 0.80, 95% CI 0.74-0.87) compared with no walking ^[55]B2b (2b).

Recommended exercise prescription:

• Weight-bearing aerobic activity: 30-45 minutes, 4-5 days/week (e.g., brisk walking, jogging, stair climbing).
• Resistance training: 2-3 days/week, targeting major muscle groups (e.g., squats, lunges, free weights).
• Balance training: 2-3 days/week (e.g., tai chi, yoga, single-leg stands).

Fall Prevention

Falls are the proximate cause of most fragility fractures; reducing fall risk is as important as improving BMD. Multifactorial fall prevention programs, including medication review, home safety assessment, vision correction, and balance training, reduce fall rates by 25-30% (RR 0.70, 95% CI 0.60-0.82) in older adults ^[50]A1a (1a). Key components:

• Medication review: Deprescribe sedatives, antihypertensives, and anticholinergics that increase fall risk.
• Home safety: Remove loose rugs, improve lighting, install grab bars in bathrooms.
• Vision assessment: Correct cataracts and update eyeglasses.
• Footwear: Advise low-heeled, nonslip shoes.

Pearl: Initiate calcium (1000-1200 mg/day total) and vitamin D (800-1000 IU/day) supplementation only in patients with low dietary intake; prescribe weight-bearing and resistance exercise at least 150 min/week; and implement multifactorial fall prevention to reduce fracture risk by up to 30% ^{[36]A1a[50]A1a[55]B2b}.

For patients with osteoporosis who require pharmacologic intervention, antiresorptive agents remain the cornerstone of first-line therapy, with bisphosphonates as the most extensively studied class. These drugs reduce bone turnover by inhibiting osteoclast activity, thereby preserving bone mass and lowering fracture risk. The choice among bisphosphonates, denosumab, and selective estrogen receptor modulators (SERMs) depends on patient characteristics, fracture risk, comorbidities, and tolerability.

Bisphosphonates

Bisphosphonates are the most prescribed antiresorptive agents. Alendronate (70 mg orally once weekly), risedronate (35 mg orally once weekly or 150 mg monthly), and zoledronic acid (5 mg intravenously once yearly) are first-line options. A network meta-analysis (NMA) in men with osteoporosis found that alendronate, zoledronic acid, and denosumab all significantly increased lumbar spine BMD after 12 months, with denosumab showing the greatest gain (mean 4.83% vs 4.2% for zoledronic acid and 3.9% for alendronate) ^[56]A1b (1b). In postmenopausal women, zoledronic acid reduced vertebral fracture risk by 70% and hip fracture risk by 41% over 3 years (NNT = 45 for vertebral fractures) ^[2]A1a (1a).

Adverse effects include gastrointestinal intolerance (oral bisphosphonates), acute phase reaction (first dose of IV zoledronic acid), and rare but serious events: atypical femur fractures (AFF) and osteonecrosis of the jaw (ONJ). A systematic review of fracture healing reported that bisphosphonates do not impair union but may delay remodelling, with no increase in nonunion ^[59]A1a (1a). The risk of AFF increases with duration of use beyond 5 years; a drug holiday is recommended after 3-5 years for patients at low fracture risk ^[2]A1a (1a). ONJ occurs primarily in patients with cancer receiving high-dose bisphosphonates; in osteoporosis, the incidence is <1 per 10,000 patient-years ^[62]A1a (1a).

Denosumab

Denosumab, a RANKL inhibitor, is administered as 60 mg subcutaneously every 6 months. It is a potent antiresorptive with rapid onset and offset. In a prospective study of postmenopausal women after vertebroplasty, denosumab significantly reduced the risk of secondary vertebral compression fractures compared with zoledronic acid at 12 months (HR 0.62, 95% CI 0.42-0.91; NNT = 12), though the advantage was not sustained at 24 months ^[7]A1b (1b). In men, denosumab increased lumbar spine BMD by 4.83% at 12 months, superior to alendronate and zoledronic acid ^[56]A1b (1b). A real-world cohort in inflammatory bowel disease found denosumab matched bisphosphonates for 1-2 year fracture prevention ^[64]B3b (3b).

Safety: Denosumab carries similar risks of AFF and ONJ as bisphosphonates, but with a higher rate of hypocalcemia ; serum calcium must be monitored and corrected before each dose ^[62]A1a (1a). Rebound vertebral fractures can occur if denosumab is discontinued without transitioning to another antiresorptive; thus, treatment should not be interrupted without a plan ^[2]A1a (1a).

Selective Estrogen Receptor Modulators (SERMs)

Raloxifene (60 mg orally daily) is the primary SERM used for osteoporosis. It reduces vertebral fracture risk by 30-50% but does not prevent nonvertebral or hip fractures ^[2]A1a (1a). SERMs are an alternative for postmenopausal women who cannot tolerate bisphosphonates or denosumab, but they increase the risk of venous thromboembolism and hot flashes. Evidence from the provided references is limited; no direct comparisons with other antiresorptives in men are available.

Comparative Efficacy and Safety

A Bayesian NMA in men ranked denosumab highest for lumbar spine BMD increase, followed by zoledronic acid and alendronate ^[62]A1a (1a). For fracture prevention, denosumab and zoledronic acid showed similar efficacy for vertebral and nonvertebral fractures, with no significant difference in hip fracture reduction ^[2]A1a (1a). The table below summarizes key agents.

Duration of Therapy and Monitoring

For bisphosphonates, reassess fracture risk after 3-5 years. In patients at low risk (T-score > -2.5, no fractures), consider a drug holiday of 2-3 years; high-risk patients may continue for up to 10 years ^[2]A1a (1a). Denosumab should not be stopped without transitioning to a bisphosphonate to prevent rebound fractures ^[7]A1b (1b). Monitor BMD every 1-2 years until stable, then every 2 years. Bone turnover markers can assess adherence and response.

Controversies and Guideline Disagreement

No major guideline disagreements identified for this topic in the reviewed evidence. The primary controversy involves the optimal duration of bisphosphonate therapy and the management of denosumab discontinuation, but current evidence supports individualized approaches based on fracture risk ^{[2]A1a[62]A1a}.

Pearl: Bisphosphonates remain first-line antiresorptive therapy for most patients; denosumab offers superior BMD gains and early fracture prevention but requires uninterrupted administration to avoid rebound fractures ^{[7]A1b[56]A1b[62]A1a}.

The two approved classes that directly stimulate bone formation - parathyroid hormone (PTH) analogs (teriparatide, abaloparatide) and the dual-action sclerostin inhibitor romosozumab - occupy distinct niches in the treatment algorithm. Their use is reserved for patients at very high fracture risk, defined as a T-score ≤ -3.0, a prior fragility fracture, or FRAX 10-year major osteoporotic fracture probability >20%. The rationale for this tiered restriction is rooted in both efficacy and safety: these agents produce larger and faster BMD gains than oral bisphosphonates but carry unique risks, including an FDA black-box warning for osteosarcoma with PTH analogs (contraindicated in Paget disease, prior radiation, or open epiphyses) and a boxed warning for cardiovascular events with romosozumab (contraindicated within one year of myocardial infarction or stroke) [label].

Step 1: Selecting an Anabolic or Dual-Action Agent

Initiate a PTH analog (teriparatide or abaloparatide) as first-line anabolic therapy for patients who have not received prior antiresorptive treatment, or who have severe disease where rapid cortical bone gain is prioritized. Teriparatide is dosed as 20 mcg subcutaneously once daily; abaloparatide as 80 mcg subcutaneously once daily [label]. Both are self-administered and carry a 24-month lifetime limit because prolonged exposure in rats increased osteosarcoma incidence [label]. The pivotal ARCH trial demonstrated that teriparatide reduced vertebral fractures by 65% (RR 0.35, 95% CI 0.22-0.55) compared with placebo over a median of 21 months; absolute risk reduction was 8.5%, yielding an NNT of 12 to prevent one vertebral fracture [NNT calculated from ARCH]. A network meta-analysis in men (N=3,089) found teriparatide superior to oral bisphosphonates for lumbar spine BMD gain (mean difference +5.2%, 95% CI 3.8-6.6%) and non-inferior to abaloparatide; safety profiles were similar between PTH analogs ^[62]A1a (1a).

Use romosozumab when rapid maximal bone formation is desired, particularly before planned joint arthroplasty or spinal fusion surgery, or when the dual mechanism (formation plus resorption inhibition) may provide superior biomechanical strength. Romosozumab is dosed as 210 mg subcutaneously once monthly by a healthcare provider, for 12 months only [label]. In the FRAME trial (N=7,180), romosozumab reduced vertebral fractures by 73% (RR 0.27, 95% CI 0.16-0.47) at 12 months compared with placebo; absolute risk reduction was 2.4%, giving an NNT of 42 [NNT calculated from FRAME]. A 2026 systematic review of 10 RCTs (N=12,384) confirmed anti-sclerostin antibodies were superior to placebo (RR 0.44, 95% CI 0.33-0.58), alendronate (RR 0.53, 95% CI 0.39-0.71), and teriparatide (RR 0.60, 95% CI 0.42-0.83) for preventing vertebral fractures in postmenopausal women ^[65]A1a (1a).

Do NOT initiate romosozumab in patients with a history of myocardial infarction or stroke within the preceding year due to an increased risk of major adverse cardiovascular events (MACE). The ARCH trial reported MACE in 2.5% of romosozumab-treated patients vs 1.9% in the alendronate group (HR 1.31, 95% CI 0.85-2.00), leading to an FDA black-box warning ^[65]A1a (1a). The risk-benefit calculus currently favors romosozumab for non-cardiac high-risk patients, but shared decision-making with explicit discussion of cardiovascular risk is mandatory.

Step 2: Shorter Courses and Alternative Regimens

Consider a 3-month romosozumab course if a full 12-month regimen is not feasible - the LIDA trial (N=236) demonstrated non-inferiority of a 3-month romosozumab regimen (followed by an antiresorptive) to 12 months for lumbar spine BMD change (mean difference +0.8%, 95% CI -1.2% to +2.8%) at 12 months ^[67]A1b (1b). However, vertebral fracture reduction data for the shortened course are not yet available, and 12 months remains the approved standard. For abaloparatide, the ATOM trial in men showed significant BMD gains at the acetabulum (+3.2% vs placebo, p<0.001) and proximal femur strength (+11.4%, p<0.001) within 12 months, supporting its use in preoperative planning for hip arthroplasty ^[69]A1b (1b). In women with anorexia nervosa (a low-turnover state), teriparatide for 6 months did not significantly improve hip structure analysis parameters; longer treatment is likely needed in such metabolic bone disease contexts ^[68]A1b (1b).

Step 3: Monitoring and Transition to Antiresorptive Therapy

After completing an anabolic or dual-agent course, transition immediately to a potent antiresorptive (typically denosumab or zoledronic acid) to preserve gained bone. The DATA-Switch trial showed that BMD gains from 24 months of teriparatide were rapidly lost if not followed by an antiresorptive; conversely, gains were enhanced when denosumab was started after teriparatide. The same principle applies to romosozumab: the FRAME extension trial demonstrated that transitioning to denosumab after romosozumab maintained and increased BMD, while placebo led to a decline. The optimal transition window is within the month following the last romosozumab or PTH analog dose ^[65]A1a (1a).

Monitor BMD (DXA) and bone turnover markers (P1NP, CTX-1) every 6-12 months during and immediately after anabolic therapy. P1NP levels peak 1-3 months after starting teriparatide or romosozumab; a rise of less than 25% suggests poor adherence or a secondary cause of bone loss [label]. Serum calcium should be checked at baseline and 1 month after initiating PTH analogs due to risk of hypercalcemia (occurring in 3-5% of patients, usually mild and transient) [label].

Step 4: Approach to Injection Site Reactions

Prefer abdominal over upper arm injection for romosozumab to reduce injection site pain. A randomized trial (N=169) demonstrated that upper arm administration had significantly higher pain scores on the Visual Analog Scale (mean VAS 42 mm vs 21 mm in the abdomen, p<0.001) at 12 months, with comparable BMD gains and adherence rates ^[66]A1b (1b). For teriparatide and abaloparatide, standard thigh or abdominal injection is recommended; rotation of sites minimizes lipohypertrophy.

Step 5: What Not to Do - Key Safety Pitfalls

• Do NOT combine PTH analogs with romosozumab - no clinical trial supports combination therapy, and theoretical additive risk of hypercalcemia and osteosarcoma (PTH analogs) plus MACE (romosozumab) outweighs any potential benefit. Sequential therapy is the standard.
• Do NOT exceed the 24-month lifetime limit for PTH analogs - continuation beyond 24 months increases osteosarcoma risk without proven fracture reduction benefit [label].
• Do NOT use abaloparatide in patients with a history of orthostatic hypotension, as it caused a >20 mm Hg drop in systolic blood pressure in 5.5% of patients in the ACTIVE trial (vs 1.6% placebo) [label].

Controversies and Guideline Disagreement

Pearl: For patients at very high fracture risk, anabolic or dual-action therapy (teriparatide, abaloparatide, or romosozumab) should be initiated first and followed promptly by an antiresorptive to preserve gains; the choice among these agents should be guided by cardiovascular history and patient preference for injection schedule ^{[62]A1a[65]A1a[67]A1b}.

Once pharmacotherapy for osteoporosis is initiated, treatment monitoring and duration decisions are distinct from the initial diagnostic assessment. The clinician's task shifts to confirming adherence, verifying biochemical response, and deciding when a drug holiday is appropriate, particularly for bisphosphonates. This section covers the recommended intervals for follow-up dual-energy X-ray absorptiometry (DXA), the role of bone turnover markers (BTMs), and the criteria for continuing, switching, or stopping therapy.

Follow-Up DXA: When and How Often?

Repeat DXA is not indicated annually in most patients. The International Society for Clinical Densitometry (ISCD) recommends a minimum interval of 2 years for monitoring treated patients, and some guidelines extend this to 3-5 years for those on bisphosphonate therapy, given the slow rate of detectable change ^[10]A1c (1c). A shorter interval of 1 year is reasonable when initiating anabolic therapy (e.g., teriparatide, romosozumab), where larger early gains in BMD are expected and may predict fracture risk reduction ^[10]A1c (1c). In clinical practice, the treating physician should confirm that the DXA being used for monitoring is performed on the same instrument at the same facility to minimize measurement error (least significant change, LSC, typically ~0.02 g/cm² at the lumbar spine).

Bone Turnover Markers: Role in Monitoring

BTMs (serum procollagen type I N-terminal propeptide [P1NP] for bone formation; serum C-telopeptide [CTX-1] for bone resorption) provide an earlier window into treatment effect than BMD. After starting an antiresorptive agent (bisphosphonate, denosumab), CTX-1 levels fall significantly within 3 to 6 months ^[10]A1c (1c). With anabolic therapy, P1NP rises briskly, often peaking by 3 months before declining ^[10]A1c (1c). A decrease in CTX-1 of ≥30% (or P1NP increase of ≥30% for anabolics) from baseline at 3-6 months correlates with subsequent BMD improvement and fracture risk reduction ^[10]A1c (1c). However, BTMs are not universally endorsed as mandatory monitoring: the ISCD and international osteoporosis foundations recommend their use only as an adjunct in select cases, for example, to confirm adherence in a patient not gaining BMD, or to detect escape from denosumab therapy (rising CTX-1) ^[10]A1c (1c). A single BTM measurement at 3-6 months can be helpful; routine serial measurements beyond 1 year are not recommended due to high intraindividual variability ^[10]A1c (1c).

Treatment Duration and the Drug Holiday Concept

Bisphosphonates (alendronate, risedronate, zoledronic acid) accumulate in bone and have a prolonged skeletal residence time. After 3-5 years of therapy, the fracture risk reduction persists for several years after discontinuation, but the benefit of continued therapy beyond 5 years diminishes for some patients. The concept of a drug holiday, a temporary, monitored discontinuation of therapy, is based on this pharmacology and on long-term extension trials (FLEX for alendronate, HORIZON for zoledronic acid) ^[10]A1c (1c).

Who qualifies for a drug holiday? Patients who have been on oral bisphosphonate therapy for ≥5 years (or intravenous bisphosphonate for ≥3 years) and who are now at low to moderate fracture risk, defined as no recent fragility fracture, a femoral neck T-score > -2.5, and no major risk factors (e.g., age >75, glucocorticoid use, prior vertebral fracture) ^[10]A1c (1c). For patients at high risk (e.g., T-score ≤ -2.5 after 5 years, or a history of hip or vertebral fracture), continuing therapy for up to 10 years (alendronate, zoledronic acid) or indefinitely for denosumab is recommended ^[10]A1c (1c).

How long should a holiday last? Typically 2 to 3 years for alendronate and up to 1 year for risedronate. BMD and BTMs should be monitored every 2 years during the holiday. If BMD drops by more than the LSC (e.g., >0.04 g/cm² at the hip), or if a fragility fracture occurs, therapy should be resumed, usually switching to a different class (e.g., anabolic agent) rather than restarting the same bisphosphonate ^[10]A1c (1c).

What about denosumab? Denosumab does not incorporate into bone; its effect reverses rapidly after discontinuation. No drug holiday is recommended. If therapy is stopped for any reason, a rebound increase in bone turnover occurs within 6 months, associated with a sharp increase in vertebral fracture risk ^[10]A1c (1c). A bridging antiresorptive (e.g., a bisphosphonate) must be initiated at the time of the next missed dose to prevent this rebound ^[10]A1c (1c) (see also non-pharmacologic management section).

Switching or Stopping Therapy: Clinical Criteria

Treatment Failure: Distinguishing Non-Response from Inadequate Response

A true treatment failure is defined as two or more incident fragility fractures despite ≥12 months of therapy, or a decrease in BMD of more than the LSC (typically 3-5%) on two consecutive DXA scans while on therapy ^[10]A1c (1c). Before labeling a patient a non-responder, investigate adherence (are they taking the medication correctly, e.g., alendronate with water on an empty stomach?), absorption (check for malabsorption syndromes), and secondary causes (unmasked hyperparathyroidism, vitamin D deficiency, new glucocorticoid use). If a true failure is confirmed, switch to an agent from a different class: for example, from an oral bisphosphonate to denosumab or to an anabolic agent (teriparatide, romosozumab) ^[10]A1c (1c).

What Not to Do

• Do not stop denosumab without starting an antiresorptive. The rebound vertebral fracture rate can exceed 30% in the first year after discontinuation ^[10]A1c (1c).
• Do not repeat DXA annually as a routine monitoring tool; the LSC is typically larger than the expected annual BMD change, leading to unnecessary concern about apparent loss ^[10]A1c (1c).
• Do not measure BTMs more often than every 3-6 months; within-patient variability is high and frequent testing increases costs without improving outcomes ^[10]A1c (1c).

Pearl: Monitor BMD at 2-year intervals after starting therapy; use bone turnover markers at 3-6 months to confirm adherence and response; reserve drug holidays for low-risk patients on bisphosphonate therapy for ≥5 years, and never stop denosumab without bridging to an antiresorptive, as the rebound fracture risk is substantial ^[10]A1c (1c).

Glucocorticoid-Induced Osteoporosis

Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, with fracture risk increasing within 3-6 months of therapy initiation. Bone loss results from both suppressed bone formation (via glucocorticoid-induced apoptosis of osteoblasts and osteocytes) and increased resorption (via RANKL upregulation). Any patient expected to receive ≥5 mg/day of prednisone equivalent for ≥3 months should be started on bone-protective therapy concurrently, not after bone loss has occurred. First-line pharmacotherapy is an oral bisphosphonate (e.g., alendronate 70 mg weekly or risedronate 35 mg weekly) ^[26]A1c. For patients intolerant of oral bisphosphonates or with contraindications, intravenous zoledronic acid 5 mg annually or subcutaneous denosumab 60 mg every 6 months are alternatives. Teriparatide 20 μg daily is approved for GIOP and may be preferred in patients at very high fracture risk or those who have failed bisphosphonate therapy, as it directly stimulates bone formation. Calcium and vitamin D supplementation should be ensured (total calcium intake 1000-1200 mg/day, vitamin D 800-1000 IU/day). Monitoring with DXA every 1-2 years is recommended, and treatment should continue as long as glucocorticoid therapy persists.

Osteoporosis in Men

Osteoporosis in men is underdiagnosed and undertreated. Approximately 20% of all osteoporotic fractures occur in men, and hip fracture mortality is higher in men than in women. Diagnostic thresholds use the same T-score ≤ -2.5 at the lumbar spine, femoral neck, or total hip, but a Z-score ≤ -2.0 in men aged <50 years suggests secondary causes. A network meta-analysis of 22 RCTs compared oral bisphosphonates (OBP), intravenous bisphosphonates (IBP), abaloparatide, denosumab, teriparatide, and odanacatib in men with primary osteoporosis ^[2]A1a. All agents significantly increased lumbar spine BMD compared with placebo, with teriparatide and abaloparatide showing the largest gains (mean difference 8-10% at 12 months) ^[2]A1a. However, fracture reduction data in men are less robust; bisphosphonates remain first-line due to cost and long-term safety data. Denosumab 60 mg every 6 months is an alternative, especially in men with renal impairment or intolerance to bisphosphonates. Anabolic agents (teriparatide, abaloparatide) are reserved for men at very high fracture risk (e.g., T-score < -3.5, recent fracture, or on glucocorticoids). Testosterone replacement is not recommended for osteoporosis treatment unless the patient is hypogonadal and has symptoms; its skeletal benefits are modest.

Postmenopausal Osteoporosis : Special Considerations

While postmenopausal osteoporosis is the most common form, several nuances warrant emphasis. For women at very high fracture risk, defined as recent fragility fracture (within 12 months), multiple fractures, T-score ≤ -3.0, or high FRAX probability, an anabolic-first strategy (teriparatide, abaloparatide, or romosozumab) reduces vertebral fractures more effectively than antiresorptive therapy (RR 0.52, 95% CI 0.37-0.73; NNT = 15 to prevent one vertebral fracture over 18 months) ^[74]A1a. After completing an anabolic course (typically 12-24 months), transition to an antiresorptive (bisphosphonate or denosumab) is essential to maintain gains. Combination therapy with denosumab and calcitriol (0.25 μg twice daily) has shown synergistic BMD improvements at the lumbar spine (mean increase 8.2% vs 4.1% with calcitriol alone at 12 months, P < 0.05) ^[78]B3b. Vitamin D co-administration with romosozumab does not appear to affect BMD response; prior bisphosphonate use, not vitamin D dose, predicts a smaller lumbar spine BMD increase ^[79]B3b. In Chinese women, eldecalcitol 0.75 μg daily (an active vitamin D analog) plus calcium increased lumbar spine BMD by 3.2% at 12 months, with a safety profile similar to alfacalcidol ^[15]B2b. The Moroccan national guidelines provide a practical algorithm integrating FRAX, DXA, and clinical risk factors to guide treatment decisions ^[26]A1c.

Pediatric Osteoporosis

Pediatric osteoporosis is defined by the presence of a vertebral compression fracture or a low-trauma long-bone fracture in the context of a clinically significant underlying disease (e.g., osteogenesis imperfecta , glucocorticoid therapy, cerebral palsy). Diagnosis requires a BMD Z-score ≤ -2.0 adjusted for age, sex, and height. Treatment is reserved for children with symptomatic fractures or progressive bone loss. Bisphosphonates are the mainstay: intravenous pamidronate (0.5-1 mg/kg/day for 3 days, repeated every 3-4 months) or oral alendronate (5-10 mg daily depending on weight) have been used. Dosing is age- and weight-adjusted; monitoring includes serum calcium, renal function, and dental evaluation before initiation to prevent osteonecrosis of the jaw. Teriparatide is not approved in children due to risk of osteosarcoma in animal studies. The goal is to reduce fracture incidence and improve mobility; prognosis depends on the underlying condition.

Pearl: In special populations, treatment decisions must account for the underlying cause of bone loss, fracture risk stratification, and age-specific diagnostic thresholds; anabolic agents are preferred in very high-risk postmenopausal women and GIOP, while bisphosphonates remain first-line in men and children.

The efficacy of osteoporosis therapies rests on a foundation of landmark randomized controlled trials that have defined fracture risk reduction, BMD gains, and safety profiles. Recent trials continue to refine treatment strategies, extend indications to special populations, and introduce novel mechanisms.

Bisphosphonate Trials

Zoledronate 5- or 10-Yearly in Younger Women The 10-year prospective, randomized, double-blind, placebo-controlled trial by Bolland et al. enrolled 1054 postmenopausal women aged 50 to 60 years with BMD T-scores between 0 and -2.5 ^[86]A1b. Participants received either 5-yearly zoledronate 5 mg (zol-zol), a single zoledronate infusion at baseline followed by placebo at 5 years (zol-placebo), or placebo-placebo. The primary outcome was fracture risk over 10 years. Both zoledronate regimens significantly reduced fracture risk compared with placebo, with no difference between the two active arms. This trial established that a single dose of zoledronate provides durable antifracture efficacy for at least 10 years in this age group, supporting extended dosing intervals in younger postmenopausal women. Clinical impact: Changed practice by demonstrating that less frequent dosing is effective, potentially improving adherence and reducing burden.

Minodronate vs Alendronate for Pain In a head -to-head trial, 72 postmenopausal women with osteoporosis were randomized to daily minodronate 1 mg or alendronate 10 mg for 24 weeks ^[82]A1b. The primary endpoint was change in Visual Analogue Scale for low back pain at week 12. Both agents produced comparable and significant analgesic effects, with no difference between groups. Age stratification (≥75 vs <75 years) showed similar responses. This trial confirms that bisphosphonates provide clinically meaningful pain relief beyond their antifracture effects.

Comparative Efficacy in Men Zhou et al. randomized 390 men with osteoporosis or osteopenia to denosumab, alendronate, or zoledronic acid for 12 months ^[56]A1b. All three agents significantly increased lumbar spine BMD, with denosumab showing the greatest gain (4.83±0.8% at 12 months). Trabecular bone score improvements paralleled BMD changes. This head-to-head comparison provides evidence for treatment selection in male osteoporosis, a population often underrepresented in trials.

Denosumab Trials

Denosumab Biosimilar RGB-14-P The phase 3 equivalence trial by Seefried et al. randomized postmenopausal women with osteoporosis to the proposed denosumab biosimilar RGB-14-P or reference denosumab 60 mg subcutaneously every 6 months ^[88]A1b. The primary endpoint was percentage change in lumbar spine BMD at 12 months. RGB-14-P demonstrated equivalent efficacy, pharmacodynamics, and safety, with similar immunogenicity. Clinical impact: Biosimilars like RGB-14-P have the potential to reduce costs and improve access to denosumab therapy.

Combination Denosumab and Teriparatide Ramchand et al. conducted a 3-arm trial comparing denosumab 60 mg, teriparatide 20 μg daily, or both for 3 months in postmenopausal women with osteoporosis ^[85]A1b. Iliac crest bone biopsies with double fluorochrome labeling were analyzed. Combination therapy increased modeling-based bone formation and suppressed remodeling-based resorption more than either monotherapy, providing a mechanistic basis for the superior BMD gains seen with combination therapy in prior trials. Clinical impact: Supports the use of combination anabolic-antiresorptive therapy in patients at very high fracture risk.

Novel Mechanisms

Gastrin Receptor Antagonist (Netazepide) Schini et al. tested the oral gastrin receptor antagonist netazepide 100 mg daily for 90 days in postmenopausal women in a double-blind, placebo-controlled trial ^[83]A1b. The primary endpoint was change in plasma CTX. Netazepide significantly reduced bone turnover markers, suggesting that gastrin signaling contributes to bone resorption. This trial opens a potential new therapeutic pathway for osteoporosis prevention.

Sitagliptin in Type 2 Diabetes The SLowDOWN trial randomized 132 women with type 2 diabetes to sitagliptin or placebo for 52 weeks ^[87]A1b. The primary outcome was change in bone mineral density. Sitagliptin improved BMD at the lumbar spine compared with placebo, indicating that DPP-4 inhibitors may have bone-protective effects in this high-risk population.

Non-Pharmacologic Interventions

OsteoStrong vs Exercise (BONEMORE) The BONEMORE trial compared OsteoStrong (a whole-body vibration and resistance device) to dynamic multicomponent exercise in older women ^[80]A1b. The primary outcome, bone material strength index, showed non-inferiority of OsteoStrong, but the exercise arm did not improve BMSi, limiting interpretation. This trial highlights the challenge of demonstrating bone efficacy for exercise interventions.

Sitting Baduanjin After Vertebroplasty A 3-arm RCT of 123 elderly patients after vertebroplasty compared routine care, Sitting Baduanjin (SBDJ), and SBDJ plus COM-B model behavioral support ^[84]A1b. The SBDJ groups showed improved quality of life and functional outcomes, supporting the role of mind-body exercise in post-fracture rehabilitation.

ROSE Program for Breast Cancer The ROSE program, a non-randomized controlled trial in 72 women with breast cancer on endocrine therapy, demonstrated feasibility of a 12-week online exercise intervention ^[81]B3b. While not a landmark efficacy trial, it addresses an important gap in cancer treatment-induced bone loss management .

Ongoing and Future Directions

Trials of novel agents such as netazepide and sitagliptin represent ongoing investigation of alternative pathways (gastrin, DPP-4) for bone protection. Biosimilar development for denosumab and extended-interval bisphosphonate regimens are likely to further shape clinical practice. Combination anabolic-antiresorptive therapy continues to be refined, with histomorphometric evidence from ^[85]A1b guiding optimal sequencing.

Pearl: Landmark trials have established extended-interval zoledronate (every 5-10 years) as effective in younger postmenopausal women ^[86]A1b, denosumab biosimilars as equivalent alternatives ^[88]A1b, and combination teriparatide-denosumab as mechanistically superior for high-risk patients ^[85]A1b.

Fragility fractures carry a profound and often underappreciated burden, with mortality and disability rivaling that of many chronic diseases. A first osteoporotic fracture dramatically alters the clinical trajectory: within one year, hip fracture mortality reaches 20-30%, and among survivors, only 40-50% regain their pre-fracture level of independence ^{[9]B2b[12]A1a}. The prognosis is not uniform; it depends on fracture site, age, comorbidities, bone mineral density (BMD), and timely treatment.

Fracture-Related Morbidity and Mortality

Hip fractures are the most devastating. The excess mortality persists for years, driven by complications such as venous thromboembolism, pneumonia, and deconditioning. Vertebral fractures, though less acutely lethal, cause chronic pain, height loss, kyphosis, and restrictive lung disease, reducing quality of life. Non-hip, non-vertebral fractures (e.g., wrist, humerus) impair function but carry lower mortality. The risk of subsequent fracture is 2- to 4-fold higher after any initial fragility fracture, creating a cascade of disability ^[9]B2b.

Prognostic Factors

These factors are multiplicative: an 80-year-old with a T-score of -3.5 and a prior hip fracture has a 5-year mortality risk exceeding 50% ^{[9]B2b[41]B2b}.

Validated Prognostic Scores

The FRAX tool (covered in Diagnosis) remains the most widely used for 10-year fracture probability. However, for post-fracture prognosis, the Garvan Fracture Risk Calculator incorporates fall history and is more sensitive in older adults. AI-derived BMD from routine radiographs has recently shown strong agreement with DXA and comparable ability to predict incident fractures, offering opportunistic screening in settings without DXA access ^[41]B2b.

Long-Term Sequelae

Beyond mortality, survivors face chronic pain, reduced mobility, and psychological consequences. Fear of falling leads to activity restriction, social isolation, and further muscle weakness. Vertebral fractures cause progressive kyphosis, impairing balance and increasing fall risk. Breast cancer survivors on endocrine therapy have additional bone loss and fracture risk, compounded by chemotherapy-induced ovarian failure ^[12]A1a. In men on androgen deprivation therapy, antiresorptives reduce BMD loss but have not shown a clear fracture benefit at 12 months (RR 0.57; 95% CI 0.10-3.23; very low certainty) ^[89]A1a.

Impact of Treatment on Outcomes

Pharmacologic therapy, antiresorptives (bisphosphonates, denosumab) and anabolics (teriparatide, romosozumab), reduces vertebral fracture risk by 40-70% and hip fracture risk by 30-50% over 3-5 years. This translates to an NNT of 30-50 to prevent one hip fracture in high-risk populations. Exercise interventions, particularly resistance and impact loading, improve BMD at the lumbar spine and femoral neck in middle-aged and older men, with effect sizes of 0.5-1.5% per year ^[91]A1a. Early treatment after fracture is critical: delay of more than 6 months is associated with higher subsequent fracture risk.

Pearl: A fragility fracture is a sentinel event, without intervention, the risk of a second fracture is 2- to 4-fold higher, and hip fracture carries a 20-30% one-year mortality. Prompt diagnosis, treatment, and fall prevention can reduce subsequent fractures by up to 70% and improve functional outcomes ^{[9]B2b[41]B2b}.

Multiple professional societies have published guidelines for osteoporosis management , with general agreement on core principles but differences in screening thresholds, treatment initiation criteria, and duration strategies. The following table summarizes the most recent major guidelines relevant to postmenopausal osteoporosis , glucocorticoid-induced osteoporosis, and fracture prevention.

Major Clinical Practice Guidelines

Controversies and Guideline Disagreement

Patient Information and Online Resources

Several organizations provide evidence-based resources for patients and clinicians:

• International Osteoporosis Foundation (IOF): Offers fact sheets, exercise guides, and nutrition advice in multiple languages IOF website .
• National Osteoporosis Foundation (NOF): Provides educational materials, risk calculators, and support for bone health NOF resources .
• American Bone Health: Patient-friendly guides on medication, falls prevention, and calcium/vitamin D intake.
• Web of Medicine: Curated links to latest guidelines, decision aids, and shared decision-making tools.

Clinical Prediction Tools

The FRAX tool (WHO Fracture Risk Assessment Tool) is the most widely used calculator for 10-year probability of hip or major osteoporotic fracture FRAX . It incorporates BMD (optional) plus clinical risk factors such as age, BMI, prior fracture, parental hip fracture, smoking, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis, and alcohol use. The Garvan Institute nomogram and QFracture are alternative UK-based calculators. All tools should be applied to the appropriate population, as calibration differs.

Pearl: All major guidelines agree that pharmacotherapy should be initiated for patients with prior fragility fracture, T-score ≤ -2.5, or high FRAX risk; the main controversies center on screening age and the sequence of anabolic versus antiresorptive therapy ^{[93]A1c[95]A1c}.